Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALRN-6924 for Chemotherapy-Induced Myelosuppression in Lung Cancer
NCT04022876Phase 1Terminated
- Sponsor
- Rein Therapeutics
- Start
- Sep 2019
- Primary completion
- Jul 2022
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of sulanemadlin in myelosuppression (3 arms), sponsored by Rein Therapeutics. Primary endpoints: Incidence, Severity, and Duration of Hematologic Toxicities and Composite Primary Endpoint of Grade 3+ Toxicity. Started Sep 2019; status: terminated.
02
Drugs
sulanemadlin
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT04022876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04022876.